Rusdany Collado Fuentes, MD
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.2% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 32.8% of the total. That places this record below the midpoint for neurology clinicians in FL, where the typical reported total is $1,698.
Across 29 payments — averaging $43.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$409
- Eisai Inc.$129
- Catalyst Pharmaceuticals, Inc.$125
- Amneal Pharmaceuticals LLC$122
- Amgen$102
- Biogen$61
- plus $301 from 11 others
Across 29 payments — averaging $23,555 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$348K
- Amgen$243K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$37K
- Eli Lilly$36K
- Acadia Pharmaceuticals Inc$20K
What the payments were for
- Speaking & faculty fees$12210%
- Food & beverage$1,12790%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 7 | $409 |
| Eisai Inc. | 2 | $129 |
| Catalyst Pharmaceuticals, Inc. | 1 | $125 |
| Amneal Pharmaceuticals LLC | 1 | $122 |
| Amgen | 1 | $102 |
| Biogen | 3 | $61 |
| EMD Serono, Inc. | 2 | $54 |
| Ironshore Pharmaceuticals Inc. | 2 | $46 |
| UCB, Inc. | 1 | $28 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Neurocrine Biosciences, Inc. | 2 | $27 |
| Neurelis, Inc. | 1 | $25 |
| Pfizer | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Phadia US Inc. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Novartis | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,249 in reported general payments places this provider in the 45th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Miami
- Diego Torres-RussottoMiami$652K
- Bruno GalloMiami$313K
- Brad HerskowitzMiami$273K
- Flavia NelsonMiami$264K
- Corneliu LucaMiami$257K
- Kottil RammohanMiami$176K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.